According to ACMG/AMP criteria, the FBLN5 variant was classified as pathogenic, consistent with autosomal recessive cutis laxa type 1A, while the TNFRSF13B variant was considered a secondary finding of uncertain clinical significance. This evidence concerns the gene FBLN5 and cutis laxa, autosomal recessive, type 1A.